Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 274-126-1
CAS number: 69808-32-8
According to OECD 423
Clinical observations in response to treatment were performed 30 minutes, 2h, and 4h post-administration and once daily thereafter during the 14-day observation period.Any visible clinical signs, discomfort and mortality were recorded. Clinical signs included changes in skin, fur, eyes and mucous membranes. Alterations in respiratory pattern, behaviour, posture, response to handling and the presence of abnormal movements were reported as well. Attention was directed to observations of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.No mortality was recorded.
It can be concluded that, according to the results obtained in this study and under the assayed experimental conditions, the test item could be ranked in the Category 4 (LD50 cut-off value of 300 < LD50 < 2000 mg/kg of body weight), of the Globally Harmonised Classification System for Chemical Substances and Mixtures.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again